MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.970
-0.060
-2.96%
Pre Market: 2.000 +0.03 +1.52% 08:50 01/27 EST
OPEN
2.080
PREV CLOSE
2.030
HIGH
2.150
LOW
1.970
VOLUME
17.23K
TURNOVER
--
52 WEEK HIGH
5.14
52 WEEK LOW
1.845
MARKET CAP
344.67M
P/E (TTM)
-1.0320
1D
5D
1M
3M
1Y
5Y
Top Biotech Stocks for Q1 2022
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. ...
Investopedia · 01/18 19:57
Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. W...
PR Newswire · 01/10 11:00
Wejo Group, ATA Creativity Global among after hour gainers
Gainers: Wejo Group (NASDAQ:WEJO) +44%, ATA Creativity Global (NASDAQ:AACG) +11%, Atreca (NASDAQ:BCEL) +6%, Akebia Therapeutics (NASDAQ:AKBA) +6%, Genfit (NASDAQ:GNFT) +3%. Losers: Annexon (NASDAQ:ANNX) -27%, Latham Group (NASDAQ:SWIM) -10%, MillerKnoll (N...
Seekingalpha · 01/04 22:09
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock ...
PR Newswire · 01/04 21:05
Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Mo...
PR Newswire · 01/04 13:30
Are Options Traders Betting on a Big Move in Akebia (AKBA) Stock?
Zacks.com · 01/02 00:26
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 12/30/2021 13:07
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation
NEW YORK, NY / ACCESSWIRE / December 29, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc.
ACCESSWIRE · 12/29/2021 15:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKBA. Analyze the recent business situations of Akebia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
71.43%Buy
0.00%Hold
14.29%Under-perform
0.00%Sell
Analyst Price Target
The average AKBA stock price target is 7.17 with a high estimate of 10.00 and a low estimate of 6.00.
High10.00
Average7.17
Low6.00
Current 1.970
EPS
Actual
Estimate
-0.48-0.36-0.24-0.12
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 232
Institutional Holdings: 102.14M
% Owned: 58.38%
Shares Outstanding: 174.96M
TypeInstitutionsShares
Increased
49
11.54M
New
10
1.20M
Decreased
36
8.70M
Sold Out
22
11.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
President/Chief Executive Officer/Director
John Butler
Chief Financial Officer/Senior Vice President/Treasurer
David Spellman
Chief Operating Officer/Senior Vice President
Michel Dahan
Senior Vice President/Secretary
Nicole Hadas
Senior Vice President
Steven Burke
Senior Vice President
Dell Faulkingham
Independent Director
Ron Frieson
Independent Director
Steven Gilman
Independent Director
Michael Heffernan
Independent Director
Michael Rogers
Independent Director
Cynthia Smith
Independent Director
Myles Wolf
Independent Director
LeAnne Zumwalt
No Data
  • All
  • Financials
  • Insiders
More
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in dialysis-dependent (DD)-CKD adult patients and the treatment of iron deficiency anemia (IDA), in non-dialysis dependent (NDD)-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.